Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Jiedu Tang is a Traditional Chinese Medicine (TCM) herbal decoction used as an adjunct therapy in oncology and for the management of diabetic complications. In patients with gastric cancer undergoing XELOX chemotherapy (capecitabine and oxaliplatin), the decoction has demonstrated immunomodulatory properties by significantly increasing the levels of CD3+ and CD4+ T cells while decreasing CD8+ T cells, thereby potentially enhancing the immune response and reducing treatment-related toxicity. Additionally, it is being investigated for its efficacy in treating diabetic peripheral neuropathy. The formulation is based on the TCM principle of 'tonifying qi and detoxifying,' utilizing a complex mixture of herbs to restore physiological balance and support the immune system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi jiedu tang.